What is the optimal treatment for a 78‑year‑old man with hypertrophic cardiomyopathy, sudden cardiac death (SCD) risk of about 1 %, NYHA (New York Heart Association) class I dyspnea, who cannot tolerate carvedilol 6.25 mg due to fatigue?

Switch to Verapamil or Diltiazem as First-Line Alternative

For this 78-year-old man with HCM (NYHA class I, low SCD risk 1.1%) who is intolerant to carvedilol due to fatigue, switch to verapamil (starting at low doses, titrating up to 480 mg/day) or diltiazem as the primary alternative therapy. 1, 2, 3

Rationale for Medication Switch

The 2011 ACCF/AHA and updated 2024 AHA/ACC guidelines establish a clear hierarchy when beta-blockers cause intolerable side effects:

• Beta-blockers are Class I first-line therapy for symptomatic HCM patients, but the guidelines explicitly acknowledge that fatigue is a recognized side effect that warrants monitoring 1
• Verapamil or diltiazem are Class I recommended alternatives specifically for patients who "have side effects or contraindications to beta-blocking drugs" 1, 3

Important Caveats for Calcium Channel Blocker Use

When initiating verapamil or diltiazem in this patient:

1. Start with LOW doses and titrate gradually - this is critical given his age (78 years) 1
2. Assess for LVOT obstruction severity first - verapamil is potentially harmful if he has:
   • Very high resting gradients (>100 mmHg)
   • Systemic hypotension
   • Severe dyspnea at rest 1, 2
3. Monitor for vasodilatory effects - both agents have vasodilating properties that can be limiting, especially in elderly patients 2, 3
4. Use caution if sinus bradycardia present 1

Alternative Beta-Blocker Trial

Before abandoning beta-blockade entirely, consider:

• Trying a different beta-blocker at a lower starting dose (e.g., metoprolol or bisoprolol instead of carvedilol)
• The carvedilol dose of 6.25 mg may have been initiated too quickly without adequate titration 4
• Start at 3.125 mg twice daily if attempting carvedilol again, with slower up-titration 4

The guidelines note that beta-blockers "should be monitored for side effects, including depression, fatigue" 1, suggesting fatigue is common but sometimes dose-dependent or agent-specific.

Why NOT Other Options at This Stage

Do NOT use:

• Dihydropyridine calcium channel blockers (nifedipine) - Class III Harm for HCM with LVOT obstruction 1
• ACE inhibitors/ARBs - potentially harmful in obstructive HCM 1
• Digoxin - potentially harmful without atrial fibrillation 1
• High-dose diuretics - can worsen obstruction 2, 3

Do NOT escalate to advanced therapies yet:

• Disopyramide - reserved for patients who fail BOTH beta-blockers AND calcium channel blockers (Class IIa) 1
• Mavacamten - indicated only after failure of first-line therapy 3
• Septal reduction therapy - only for NYHA Class III-IV with severe drug-refractory symptoms 1

This patient is NYHA Class I (minimal symptoms), so invasive therapies are explicitly contraindicated 1.

ICD Consideration

With SCD risk of 1.1%, this patient falls into a low-risk category (<4% 5-year risk). The 2024 guidelines would classify this as Class 2b or 3 (ICD may be considered but not routinely recommended) 5. Focus should remain on symptom management rather than primary prevention ICD at this risk level.

Monitoring Strategy

Once verapamil/diltiazem is initiated:

• Titrate based on symptom response, not gradient reduction 2, 3
• Monitor blood pressure and heart rate closely given age
• Reassess symptoms at 1-2 weeks and adjust dosing accordingly
• If symptoms persist despite adequate calcium channel blocker therapy, then consider adding disopyramide or referral to HCM center for mavacamten evaluation 3